Trzeci konkurs w ramach programu TRANSCAN-3 (Joint Transnational Call 2023) obejmuje finansowanie projektów z tematu: „Translational research on cancer epigenetics”.
Dofinansowanie można przeznaczyć na realizację badań przemysłowych i prac rozwojowych w zakresie tematycznym:
Aim 1) The role of epigenetics in cancer initiation and progression. These studies may aim to validate novel epigenetics-based biomarkers to improve detection, diagnosis, prognosis of cancers or response to therapies (using recently developed innovative approaches, multiomic approaches, single-cell analysis, patient-derived organoids, patient-derived xenografts, tumour samples collected from retrospective and/or prospective cohorts of patients or clinical trials).
Specific aim 1.1: To understand cancer initiation and progression by characterisation of the epigenetic landscape.
Specific aim 1.2: To define epigenetic features of cells in the tumour microenvironment that may promote tumour progression (e.g., immune cells, vascular cells, microbiota).
Specific aim 1.3: To study the role of epigenetic modifications as predictors of cell persistence or treatment resistance.
Specific aim 1.4: To validate epigenetic markers useful to improve early detection and diagnosis by exploring the correlation between epigenetics and clinical cancer manifestation.
Aim 2) Validation of new epigenetics-based therapeutic strategies to limit cancer progression, prevent relapse/recurrence or increase the efficiency or reduce toxicity of existing anti-cancer therapies.
Specific aim 2.1: To validate novel therapeutic targets (novel targets should be evaluated in translational studies with regard to their impact on treatment efficacy, safety and patient reported outcomes).
Specific aim 2.2: To study the potential use of epigenetic modulators to overcome resistance to anti-cancer therapies.
Specific aim 2.3: To develop novel epidrugs/therapeutic approaches, through phase I and II clinical trials (investigating combinations of available treatments, new therapeutics, new administration schemes, etc.) to improve safety and efficacy of treatments (objective responses; patient reported outcomes regarding morbidity and quality of life; …).
Specific aim 2.4: To develop novel theranostic approaches involving epigenetics of cancer. Approaches combining diagnostic (imaging technics) and targeted treatment to detect cancer cells and assess treatment efficacy (radionuclide, radiopharmaceuticals, nanoparticles, nanomaterial, …).
Budżet konkursu wynosi 600 000 euro na wszystkie projekty z udziałem polskich partnerów a maksymalny poziom dofinansowania na projekt to 200 000 euro.
Rozpoczęcie naboru wniosków wstępnych: 29/05/2023
Zakończenie naboru wniosków wstępnych: 21/07/2023; godz. 12.00
Szczegółowe informacje dostępne są na stronie: https://www.gov.pl/web/ncbr/transcan-3-era-net-sustained-collaboration-of-national-and-regional-programmes-in-cancer-research2